{"analyses":[{"groupDescription":"Comparison of proportion of patient's complete response rate between HLHR13 and HOD99 (NCT00145600) unfavorable risk arm 2 (UR2).","groupIds":["OG000"],"nonInferiorityType":"SUPERIORITY","pValue":"0.004","statisticalMethod":"Fisher Exact"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"24","upperLimit":"46","value":"35"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"77"}],"units":"Participants"}],"description":"To evaluate the safety of AEPA/CAPDac, as well as the efficacy (early complete response) after 2 cycles of AEPA chemotherapy in high-risk patients with Hodgkin Lymphoma (HL).","dispersionType":"95% Confidence Interval","groups":[{"description":"Ann Arbor stage IIB, IIIB, IVA, or IVB participants receive:\n\n2 cycles of AEPA chemotherapy: (A) Brentuximab vedotin 1.2 mg/kg IV (intravenous) days 1, 8 and 15, (E) Etoposide 125 mg/m\\^2 IV days 1-5, (P) Prednisone 60 mg/m\\^2/day PO (orally) days 1-15, (A) Doxorubicin 40 mg/m\\^2 IV days 1 and 15), Followed by 4 cycles of CAPDac: (C) Cyclophosphamide 500 mg/m\\^2 IV days 1 and 8, (A) Brentuximab vedotin 1.2 mg/kg IV days 1 and 8, (P) Prednisone 40 mg/m\\^2/day PO days 1-15, (Dac) Dacarbazine 250 mg/m\\^2 IV days 1-3.).\n\nFilgrastim 5 mcg/kg subcutaneous (SC) as clinically indicated.\n\nFor those with lymph nodes that do not go into remission after 2 courses of AEPA chemotherapy, radiation therapy is given.","id":"OG000","title":"AEPA/CAPDac"}],"paramType":"NUMBER","populationDescription":"All the evaluable participants that completed the first 2 cycles of chemotherapy.","reportingStatus":"POSTED","timeFrame":"After the first 2 cycles of chemotherapy (at 2 months from enrollment for each participant)","title":"Complete Response Rate Estimate for All Evaluable Participants","type":"PRIMARY","unitOfMeasure":"percentage of participants"}